SCHEMBL14937796

SCHEMBL14937796

CN(C(=O)n1cnc(-c2cccnc2)c1)[C@H]1CC[C@H](OCc2ccccc2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 2/20 0.47
CES2 O00748 1/20 0.47
CYP2E1 P05181 3/20 0.43
CYP2A6 P11509 3/20 0.43
CYP2C9 P11712 3/20 0.43
CYP2B6 P20813 3/20 0.43
CYP2C19 P33261 3/20 0.43
CYP3A4 P08684 2/20 0.43
CYP2D6 P10635 1/20 0.43
CYP11B1 P15538 5/20 0.41
CYP11B2 P19099 5/20 0.41
AOC3 Q16853 2/20 0.40
USP19 O94966 2/20 0.39
CYP19A1 P11511 3/20 0.39
CHRM2 P08172 1/20 0.39
CHRM1 P11229 1/20 0.39
CHRM3 P20309 1/20 0.39
DYRK1A Q13627 1/20 0.39
FNTA P49354 1/20 0.38
FNTB P49356 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14937794 1.00 FAAH (0.47) FAAHCES2CYP2E1CYP2A6CYP2C9
SCHEMBL427990 0.93 FAAH (0.52) FAAHCES2AOC3USP19
SCHEMBL428099 0.83 DRD2 (0.50) FAAHCES2CYP2E1CYP2A6CYP2C9
SCHEMBL14937999 0.83 FAAH (0.43) FAAHCES2AOC3USP19
SCHEMBL14938000 0.83 FAAH (0.43) FAAHCES2AOC3USP19
SCHEMBL427890 0.82 FAAH (0.55) FAAHCES2CYP2E1CYP2A6CYP2C9
SCHEMBL426094 0.82 FAAH (0.66) FAAHCES2CYP2E1CYP2A6CYP2C9
SCHEMBL427415 0.82 DRD2 (0.52) FAAHCES2CYP2E1CYP2A6CYP2C9
SCHEMBL424140 0.81 FAAH (0.67) FAAHCES2CYP2E1CYP2A6CYP2C9
SCHEMBL526132 0.80 KDM4E (0.41) FAAHCES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2606035-B1 PROCES FOR THE SYNTHESIS OF SUBSTITUTED UREA COMPOUNDS BIAL - PORTELA & CA S A (PT) 2017-09-06 EP disclosed
US-9458111-B2 Process for the synthesis of substituted urea compounds BIAL—PORTELA & CA, S.A. (PT) 2016-10-04 US disclosed
US-9458111-B2 Process for the synthesis of substituted urea compounds BIAL—PORTELA & CA, S.A. (PT) 2016-10-04 US disclosed
US-9458111-B2 Process for the synthesis of substituted urea compounds BIAL—PORTELA & CA, S.A. (PT) 2016-10-04 US disclosed
US-20130123493-A1 PROCESS FOR THE SYNTHESIS OF SUBSTITUTED UREA COMPOUNDS BIAL - PORTELA & CA, S.A. (PT) 2013-05-16 US disclosed
US-20130123493-A1 PROCESS FOR THE SYNTHESIS OF SUBSTITUTED UREA COMPOUNDS BIAL - PORTELA & CA, S.A. (PT) 2013-05-16 US disclosed
US-20130123493-A1 PROCESS FOR THE SYNTHESIS OF SUBSTITUTED UREA COMPOUNDS BIAL - PORTELA & CA, S.A. (PT) 2013-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123493-A1 PROCESS FOR THE SYNTHESIS OF SUBSTITUTED UREA COMPOUNDS UTS2R, ARG1, PRMT1 FAAH 2166/4885CES2 463/4885CYP2E1 411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.